← Leaderboards
Nicholas Mark Levinson
University Of Minnesota
$8,462,997
Attributed
$9,901,719
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,901,719 · 9
By mechanism
R01$7,100,085 · 4
R33$1,122,951 · 1
R00$744,528 · 1
R21$610,005 · 1
K99$180,000 · 1
F32$144,150 · 1
Top collaborators
- David Dale Thomas5 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Brock Grill$11,957,321
- Ian Albert Tonks$3,935,085
- David Dale Thomas$44,926,284
- Deanna M. Koepp$1,326,223
- Damien M Rasmussen$97,756
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsComplexPhosphotransferasesKinase InhibitorBindingMolecular ConformationFluorescence Resonance Energy TransferProtein KinaseSuccessScaffoldStructureProteinsInsightActive SitesNext GenerationSiteSignal TransductionMediatingInhibitor/AntagonistDesignResistanceMeasurementSmall MoleculeSpectrum Analysis
Grant awards (31)
A transformative drug discovery platform for allosteric kinase inhibitors$706,093
R01 · FY2025 · CA · contact PI
Allosteric mechanisms driving paradoxical activation of RAF kinases$473,037
R01 · FY2025 · CA · contact PI
Targeting allosteric scaffolding functions of Aurora kinase A in cancer$354,563
R01 · FY2025 · CA · contact PI
Allosteric mechanisms driving paradoxical activation of RAF kinases$470,464
R01 · FY2024 · CA · contact PI
A transformative drug discovery platform for allosteric kinase inhibitors$431,555
R01 · FY2024 · CA · contact PI
Targeting allosteric scaffolding functions of Aurora kinase A in cancer$336,835
R01 · FY2024 · CA · contact PI
A transformative drug discovery platform for allosteric kinase inhibitors$571,741
R01 · FY2023 · CA · contact PI
Targeting allosteric scaffolding functions of Aurora kinase A in cancer$347,471
R01 · FY2023 · CA · contact PI
A transformative drug discovery platform for allosteric kinase inhibitors$571,741
R01 · FY2022 · CA · contact PI
Time-resolved FRET-based allostery sensors for any protein kinase drug target$370,320
R33 · FY2022 · CA · contact PI
Targeting allosteric scaffolding functions of Aurora kinase A in cancer$347,471
R01 · FY2022 · CA · contact PI
Decoding the dynamic mechanism of allosteric activation in the cyclin-dependent kinase Cdk2$308,000
R01 · FY2022 · GM · contact PI
A transformative drug discovery platform for allosteric kinase inhibitors$596,314
R01 · FY2021 · CA · contact PI
Time-resolved FRET-based allostery sensors for any protein kinase drug target$377,096
R33 · FY2021 · CA · contact PI
Targeting allosteric scaffolding functions of Aurora kinase A in cancer$353,800
R01 · FY2021 · CA · contact PI
Decoding the dynamic mechanism of allosteric activation in the cyclin-dependent kinase Cdk2$308,000
R01 · FY2021 · GM · contact PI
Time-resolved FRET-based allostery sensors for any protein kinase drug target$375,535
R33 · FY2020 · CA · contact PI
Decoding the dynamic mechanism of allosteric activation in the cyclin-dependent kinase Cdk2$308,000
R01 · FY2020 · GM · contact PI
Decoding the dynamic mechanism of allosteric activation in the cyclin-dependent kinase Cdk2$308,000
R01 · FY2019 · GM · contact PI
A novel time-resolved fluorescence-based high-throughput screening technology for discovering allosteric kinase inhibitors$149,380
R21 · FY2019 · CA · contact PI
Decoding the dynamic mechanism of allosteric activation in the cyclin-dependent kinase Cdk2$307,000
R01 · FY2018 · GM · contact PI
A novel time-resolved fluorescence-based high-throughput screening technology for discovering allosteric kinase inhibitors$231,000
R21 · FY2018 · CA · contact PI
Kinome-Wide Spectroscopic Study of Drug Binding Site Electrostatics$248,176
R00 · FY2017 · GM · contact PI
A novel time-resolved fluorescence-based high-throughput screening technology for discovering allosteric kinase inhibitors$229,625
R21 · FY2017 · CA · contact PI
Kinome-Wide Spectroscopic Study of Drug Binding Site Electrostatics$248,176
R00 · FY2016 · GM · contact PI
Kinome-Wide Spectroscopic Study of Drug Binding Site Electrostatics$248,176
R00 · FY2015 · GM · contact PI
Kinome-Wide Spectroscopic Study of Drug Binding Site Electrostatics$90,000
K99 · FY2013 · GM · contact PI
Kinome-Wide Spectroscopic Study of Drug Binding Site Electrostatics$90,000
K99 · FY2012 · GM · contact PI
Measuring static and dynamic electric fields in proteins$51,326
F32 · FY2011 · GM · contact PI
Measuring static and dynamic electric fields in proteins$47,606
F32 · FY2010 · GM · contact PI
Measuring static and dynamic electric fields in proteins$45,218
F32 · FY2009 · GM · contact PI